1. Home
  2. MESO vs SCS Comparison

MESO vs SCS Comparison

Compare MESO & SCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • SCS
  • Stock Information
  • Founded
  • MESO 2004
  • SCS 1912
  • Country
  • MESO Australia
  • SCS United States
  • Employees
  • MESO N/A
  • SCS N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • SCS Office Equipment/Supplies/Services
  • Sector
  • MESO Health Care
  • SCS Consumer Discretionary
  • Exchange
  • MESO Nasdaq
  • SCS Nasdaq
  • Market Cap
  • MESO 1.3B
  • SCS 1.2B
  • IPO Year
  • MESO N/A
  • SCS 1998
  • Fundamental
  • Price
  • MESO $11.06
  • SCS $10.65
  • Analyst Decision
  • MESO Buy
  • SCS Buy
  • Analyst Count
  • MESO 4
  • SCS 1
  • Target Price
  • MESO $18.00
  • SCS $16.00
  • AVG Volume (30 Days)
  • MESO 205.5K
  • SCS 1.2M
  • Earning Date
  • MESO 08-28-2025
  • SCS 06-25-2025
  • Dividend Yield
  • MESO N/A
  • SCS 3.78%
  • EPS Growth
  • MESO N/A
  • SCS 37.12
  • EPS
  • MESO N/A
  • SCS 1.04
  • Revenue
  • MESO $5,670,000.00
  • SCS $3,217,700,000.00
  • Revenue This Year
  • MESO $178.09
  • SCS $4.20
  • Revenue Next Year
  • MESO $305.06
  • SCS $4.09
  • P/E Ratio
  • MESO N/A
  • SCS $10.18
  • Revenue Growth
  • MESO N/A
  • SCS 2.64
  • 52 Week Low
  • MESO $5.78
  • SCS $9.32
  • 52 Week High
  • MESO $22.00
  • SCS $14.74
  • Technical
  • Relative Strength Index (RSI)
  • MESO 50.02
  • SCS 50.37
  • Support Level
  • MESO $10.32
  • SCS $10.58
  • Resistance Level
  • MESO $10.86
  • SCS $10.99
  • Average True Range (ATR)
  • MESO 0.35
  • SCS 0.43
  • MACD
  • MESO 0.00
  • SCS -0.01
  • Stochastic Oscillator
  • MESO 45.04
  • SCS 56.18

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About SCS Steelcase Inc.

Steelcase Inc is a furniture company based in the United States. Its brands, such as Steelcase, AMQ, Coalesse, Designtex, and others, offer a portfolio of furniture and architectural products and services designed to help customers create workplaces. It markets its products and services to businesses and organizations predominantly through a network of dealers and also sells to consumers in markets around the world through web-based and retail distribution channels. The company's reportable segments include the Americas, which generates key revenue, and the International segment.

Share on Social Networks: